(2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE Chemical Properties

Boiling point:

890.2±65.0 °C(Predicted)

Density 

1.404

storage temp. 

Sealed in dry,2-8°C

solubility 

DMSO: ≥20mg/mL

pka

11.39±0.20(Predicted)

form 

powder

color 

light yellow to light brown

optical activity

[α]/D +50 to +70°, c = 0.2 in methanol

Safety Information

WGK Germany 

3

(2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE Usage And Synthesis

Description

The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor, have been implicated in the development and progression of several human cancers. PHA-665752 is an ATP-competitive, active-site inhibitor of the catalytic activity of c-Met kinase (K_i = 4 nM; IC₅₀ = 9 nM). It exhibits >50-fold selectivity for c-Met over a panel of tyrosine and serine/threonine kinases. PHA-665752 can inhibit c-Met phosphorylation, as well as cell proliferation and cell motility, of various tumor cells (IC₅₀s = 18-50 nM). It also inhibits signal transduction downstream of c-Met, interfering with the activation of Gab-1 adaptor protein, ERK1/2, Akt, STAT3, PLC-γ, and focal adhesion kinase in multiple tumor cell lines. In a gastric carcinoma xenograft model, 25 mg/kg PHA-665752 was shown to reduce tumor growth in mice by inhibiting c-Met activation.

Chemical Properties

Yellow powder crystal

Uses

PHA-665752 ia a c-Met kinase inhibitor. PHA-665752 is ATP-competitive, an active-site inhibitor with greater than 50-fold selectivity for c-Met vs a panel of tyrosine and serine-threonine kinases.

Definition

ChEBI: A member of the class of indolones that is 1,3-dihydro-2H-indol-2-one which is substituted by a (2,6-dichlorobenzyl)sulfonyl group at position 5 and by a (1H-pyrrol-2-yl)methylidene group at position 2, the pyrrole rin of which is substituted by methyl groups at positions 3 and 5, and by a [2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl group at position 4 (the Z,R isomer).

Biological Activity

Potent, selective and ATP-competitive inhibitor of MET kinase (IC 50 values are 9, 68, 200, 1400, 3000, 3800 and 6000 nM for MET, Ron, Flk-1, c-abl, FGFR1, EGFR and c-src respectively and > 10000 nM for IGF-IR, PDGFR, AURORA2, PKA, PKB α , p38 α , MK2 and MK3). Antitumor agent; inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.

Biochem/physiol Actions

PHA-665752 ia a c-Met kinase inhibitor. PHA-665752 is ATP-competitive, an active-site inhibitor with greater than 50-fold selectivity for c-Met vs a panel of tyrosine and serine-threonine kinases.

in vivo

pha-665752 inhibits c-met phosphorylation as well as tumor growth in both s114 and gtl-16 implanted xenograft athymic mice [1].

storage

Store at +4°C

References

[1] christensen jg1, schreck r, burrows j, kuruganti p, chan e, le p, chen j, wang x, ruslim l, blake r, lipson ke, ramphal j, do s, cui jj,cherrington jm, mendel db. a selective small molecule inhibitor of c-met kinase inhibits c-met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. cancer res. 2003 nov 1;63(21):7345-55.

(2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE(477575-56-7)Related Product Information

• PHA-848125
• Bortezomib
• Tivantinib (ARQ 197)
• SU 11274
• Veliparib
• Crizotinib
• Olaparib
• PHA-665752
• R)-N-METHYL-2-PYRROLIDIN-1-YLMETHYL-PYRROLIDINE
• p-(ethylsulfonyl)-anilin
• 1-(Cloromethyl)-4,5-dihydro-1H-imidazole hydrochloride
• SU 5416
• (R)-(-)-1-(2-Pyrrolidinylmethyl)pyrrolidine